systematic_review
    2012

    Levodopa content and safety of Mucuna pruriens preparations: an analytical review

    Lampariello LR, Cortelazzo A, Guerranti R

    Published in Journal of Traditional and Complementary Medicine

    Key Findings

    Levodopa content of commercial Mucuna products varies widely, creating dosing unpredictability and risk of dopaminergic side effects.

    Conclusions

    Product standardisation is the key safety issue.

    Limitations

    Analytical review, no clinical outcomes.

    Supplements Studied

    Levodopa content of commercial Mucuna products varies widely, creating dosing unpredictability.

    Related Health Concerns

    Parkinson's Disease

    Study Details

    Year:2012
    Quality Score:5/10

    Access Study

    View on DOIView on PubMedOriginal Source

    This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.